Company profile
TUHURA BIOSCIENCES, INC./NV
NASDAQ:HURABiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| PEMBROLIZUMAB | phase4 | — | 302 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (5)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06940440 | phase1 | recruiting | 2025-10-01 | 2026-05-31 | TuHURA Biosciences, Inc. | IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC) |
| NCT04925713 | phase1 | completed | 2021-06-10 | 2021-10-07 | TuHURA Biosciences, Inc. | IFx-Hu2.0 for the Treatment of Patients With Skin Cancer |
| NCT04160065 | phase1 | completed | 2020-03-03 | 2023-10-19 | TuHURA Biosciences, Inc. | Immunotherapy With IFx-Hu2.0 Vaccine for Advanced Non-melanoma Skin Cancers |
| NCT06947928 | phase2_3 | recruiting | 2025-12-11 | 2027-03-31 | TuHURA Biosciences, Inc. | Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma |
| NCT03655756 | — | completed | 2018-11-05 | 2020-07-10 | TuHURA Biosciences, Inc. | pDNA Intralesional Cancer Vaccine for Cutaneous Melanoma |
FDA applications (0)
No records yet.